Published On: Fri, May 12th, 2017

Broker Changes For Mirati Therapeutics, Inc. (MRTX)


Recently stock market analysts have updated their consensus ratings on shares of Mirati Therapeutics, Inc. (MRTX).

Most recent broker ratings

03/10/2017 – Mirati Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 10 price target on the stock.

03/10/2017 – Mirati Therapeutics, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 5.5 price target on the stock.

08/19/2016 – Mirati Therapeutics, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 7 price target on the stock.

06/06/2016 – Mirati Therapeutics, Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 27 price target on the stock.

06/06/2016 – Mirati Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 27 price target on the stock.

06/06/2016 – Mirati Therapeutics, Inc. had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 23 price target on the stock.

06/06/2016 – Mirati Therapeutics, Inc. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 20 price target on the stock.

05/06/2016 – Mirati Therapeutics, Inc. was upgraded to “market outperform” by analysts at Avondale Partners. They now have a USD 20 price target on the stock.

03/01/2016 – SunTrust began new coverage on Mirati Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 32 price target on the stock.

06/01/2015 – Mirati Therapeutics, Inc. was downgraded to “hold” by analysts at Brean Capital. They now have a USD 34 price target on the stock.

05/12/2015 – Mirati Therapeutics, Inc. was downgraded to “hold” by analysts at Zacks.

07/11/2014 – Mirati Therapeutics, Inc. was upgraded to “focus list” by analysts at Johnson Rice.

06/16/2014 – Mirati Therapeutics, Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 28 price target on the stock.

Mirati Therapeutics, Inc. has a 50 day moving average of 4.61 and a 200 day moving average of 5.25. The stock’s market capitalization is 81.05M, it has a 52-week low of 3.15 and a 52-week high of 19.25.

The share price of the company (MRTX) was down -9.72% during the last trading session, with a high of 3.65 and the volume of Mirati Therapeutics, Inc. shares traded was 337205.